-transparent.png){kind=logo}
A serious delayed neurotoxicity marked by encephalopathy and cortical blindness has occurred in patients treated with fludarabine. This toxicity had only been reported in patients receiving high doses (ie, aplasia-inducing). We describe a similar subacute neurological deterioration occurring in two patients, including one who received only low doses of this agent. Neurologic vulnerability to low doses of fludarabine may be multifactorial and at present cannot be predicted. Continued caution in the use of this new antineoplastic agent is appropriate.
Related Publications
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
October 1986,
Cancer treatment reports,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
February 2014,
Emergency medicine clinics of North America,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
January 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
January 2011,
The Annals of pharmacotherapy,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
July 1980,
Annals of internal medicine,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
January 1985,
Lancet (London, England),
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
March 1988,
The New England journal of medicine,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
March 1983,
British journal of cancer,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
December 1978,
Cancer treatment reports,
D E Merkel, and
N L Griffin, and
K Kagan-Hallet, and
D D Von Hoff
September 1991,
Gynecologic oncology,
